Neovacs Aims To Complete Recruitment For Research
Edison | Aug 01, 2016 07:58AM ET
Neovacs (PA:ALNEV)'s lead project, IFN-Kinoid (IFN-K) for lupus, started a 178-patient EU, US and RoW Phase II in Q315. It expects data by mid-2017. This is based on clinical response and measurement of the interferon signature (IS), a diagnostic marker of lupus.
CKD, a leading Korean pharmaceutical company, partnered the product for Korea in 2015; marketing may start in 2018. Neovacs plans to partner IFN-K, implying possible launches in 2021. VEGF-Kinoid for cancer and AMD could start Phase I in H117 and a type 1 diabetes kinoid is in preclinical testing. Cash in December 2015 was €6.1m; a French rights issue in June 2016 raised €8m gross at €0.85/share.
Phase IIb data due June 2017 then partnering
Neovacs is aiming to complete recruitment into the 178-patient Phase IIb by late summer 2016, with an expected June 2017 release of preliminary data on the two combined, 36-week endpoints. Neovacs has FDA approval to include US centres.
The trial is based on the neutralisation of the interferon gene expression signature, now seen as a key lupus marker. It will also score clinical responses assessed using the BILAG system.
Two IFN-based candidates from AstraZeneca have shown that patients with high interferon signatures respond better to IFN control. Neovacs intends to find a partner to run and fund Phase III studies from 2018. This could enable a US and EU regulatory filing by 2020 and possible marketing from 2021.
To read the entire report Please click on the pdf File Below
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.